Despite individual regulatory bodies having their own unique set of requirements, for most organisations, the challenges associated with annual product quality reviews (APQR) are largely the same. Issues with fragmented systems and paper-based processes prove increasingly burdensome.
With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.
The city is investing in the future by establishing a modern campus and strengthening Mainz as a hub for life sciences. Space with convenient transport connections close to the city centre is available to found or relocate start-ups, companies and research facilities.
To address the demands of a growing population and enhance food and nutrition security, a transition from traditional chemical-derived production is essential. Biomanufacturing, known for its efficient use of natural resources, offers an ideal solution. Acies Bio recently added fermentation capacity and more versatile equipment for downstream processing and formulation.
This scrappy young city in the heart of Europe is rapidly becoming a magnet for successful start-ups and companies looking for plenty of room to grow, as well as a culture of cooperation and trust.
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Ikxinta, a life sciences advisory firm that originated in the Basque Country in 2018, collaborates with scientists, industry innovators, and investors to propel clients in scientific frontiers
Manufacturing of COVID vaccines showed that large-scale production of lipid nanoparticles (LNPs) as a delivery vehicle for mRNA vaccines is already possible. As nanocarrier-based formulations became mainstream, however, insufficiencies in existing technologies for routine GMP manufacturing became apparent. LEON is committed to bridging these technology gaps through its unique FR-JET technology and innovative manufacturing equipment.
Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.
For 25 years now, BioM has been the network organisation of the biotechnology sector in Munich and Bavaria. To shape the future of biotechnology, BioM identifies relevant and sustainable local, regional and global trends and creates a unique ecosystem for innovation and growth.